...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: BIO CEO Slides Up

You say:

"Said another way, the drug certainly could be playing a very strong factor in the patient group on MACE reductions which is yet another reason why they've slowed to a crawl."

That presumably would be true for patients taking Apabetalone. But not necessarily so for the placebo arm as it is the basis of this medical trial yet to be proven.

 

IMO...Koo 

 

Share
New Message
Please login to post a reply